Compare Arista Networks Inc (ANET) vs GSK plc (GSK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Arista Networks Inc vs GSK plc — how do they compare? Arista Networks Inc trades at $187.83 (market cap $235.41B), while GSK plc trades at $52.5 (market cap $103.72B). The key difference: Arista Networks Inc is far larger — about 2.3× GSK plc's market cap, and GSK plc pays a 3.4% dividend while Arista Networks Inc pays none. Which is the better fit depends on your goals.
| ANET | GSK | |
|---|---|---|
Market Cap | $235.41B | $103.72B |
Sector | Technology | Health |
52-Week High | $186.96 | $61.18 |
52-Week Low | $107.37 | $36.20 |
Enterprise Value | $223.06B | $124.33B |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Arista Networks (ANET) trades at $186.96, up 1.23% with strong technical momentum as price approaches resistance at $189. The company demonstrates robust fundamentals with 2025 revenue of $9.01B and net income of $3.51B (38.32% margin), though valuation metrics remain elevated with P/E of 64.25. Recent earnings beats and AI infrastructure tailwinds support positive sentiment.
Arista presents growth potential from AI networking demand with 75% analyst buy ratings and $192.82 consensus target, but faces risks from high valuation multiples and competitive pressures. The stock's technical setup suggests near-term resistance testing with support at $180, while fundamental strength supports long-term growth outlook.
GSK trades at $52.78, up 0.59% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.27. Revenue grew to $32.67B in 2025, with a net income margin of 17.78%. Recent news includes FDA approval for Utebzi and a $10.6B acquisition of Nuvalent to bolster its oncology pipeline.
GSK presents a balanced outlook with solid profitability and strategic growth in oncology, but faces risks from clinical trial setbacks and competitive pressures. Analyst sentiment is mixed, with 31% buy ratings, suggesting cautious optimism amid pipeline execution uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arista Networks Inc
Arista Networks is a software and hardware provider for the networking solutions sector. Operating as one business unit, software, switching, and router products are targeted for high-performance networking applications, while service revenue comes from technical support. Customer markets include data centers, enterprises, service providers, and campuses. The company is headquartered in Santa Clara, California, and generates most of its revenue in the Americas.
Read more on ANET →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
